| n (%) | M (SD) | MD (min–max) |
---|---|---|---|
Sex | |||
 Female | 48 (34.0) |  |  |
 Male | 93 (66.0) |  |  |
Age | Â | 42.0 (7.2) | Â |
Age of first opioid use | Â | 18.9 (3.4) | Â |
Opioid dose (methadone equivalents) |  | 108.9 (53.5) | 100.0 (15–300) |
Duration of current OAT | |||
 < 1 year | 17 (12.1) |  |  |
 1–4 years | 36 (25.5) |  |  |
 5–9 years | 34 (24.1) |  |  |
 > 10 years | 54 (38.3) |  |  |
Opioid agonists prescribeda | |||
 Methadone | 76 (53.9) |  |  |
 SROM | 22 (15.6) |  |  |
 DAM | 79 (56.0) |  |  |
 Buprenorphine | 7 (5.0) |  |  |
Lifetime BZD use | 125 (88.7) | Â | Â |
Prolonged BZD useb | 61 (43.6) | Â | Â |
Current BZD use | 82 (58.2) | Â | Â |
Former BZD use | 43 (30.5) | Â | Â |
Age at first BZD use | Â | 22.1 (7.2) | Â |
BZD dose (daily diazepam dose equivalents) |  | 24.0 (29.1) | 20.0 (0–210) |
Current use of other substancesc (excluding prescription opioids, BZD, and TCA) | |||
 None | 56 (39.7) |  |  |
 1 | 63 (44.7) |  |  |
 2 | 18 (12.8) |  |  |
 3 | 2 (1.4) |  |  |
 Missing | 2 (1.4) |  |  |
HIV seropositive | 10 (7.1) | Â | Â |
HCV seropositive | 97 (68.8) | Â | Â |
Non-substance related mental disorders | |||
 None | 47 (33.3) |  |  |
 1 | 58 (41.1) |  |  |
 2 | 34 (24.1) |  |  |
 3 | 2 (1.4) |  |  |